Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMenghan LiuWLWenjing LiYYYan Yan

Discussion

Loading...

Member takes

Overview

Phase 2 study shows 90% overall response rate in relapsed/refractory multiple myeloma patients with extramedullary disease, implying a promising therapy.

Key Points

  • To evaluate the efficacy and safety of Aponermin + KT-DECP regimen in patients with relapsed/refractory multiple myeloma and extramedullary disease.
  • Multicenter, single-arm, phase 2 study enrolling 31 patients with extramedullary disease-confirmed relapsed/refractory multiple myeloma.
  • Patients received Aponermin and KT-DECP regimen for 4-6 cycles, with radiotherapy added if needed.
  • Primary endpoint was overall response rate after two cycles, with secondary endpoints including complete remission and safety.
  • Overall response rate after two cycles was 90% (18 out of 20 patients).
  • Median progression-free survival data was not reached, with a 5-month PFS rate of 77%.
  • Common adverse events included thrombocytopenia (65.2%) and granulocytopenia (56.5%).

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df5chttps://doi.org/10.1182/blood-2025-2280
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study2025
  2. 2Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study2025
  3. 3Real-world safety and efficacy of aponermin and daratumumab-based regimens in patients with multiple myeloma2025
  4. 4Real-world efficacy and safety of the carfilzomib–pomalidomide–dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study2026
  5. 5Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study2024 · 5 citations